Biotechnology Companies in United Kingdom (UK)

For supermarkets, food producers, and farmers, we offer modular insect farms that convert food waste into animal feed. Our technology helps reduce emissions, mitigate food waste, and replace deforestation-linked soy.

TEK Optima Research is a leading provider of advanced imaging systems and AI-powered software solutions, based in Wimborne, Dorset, UK.

We specialize in designing and manufacturing high-performance hardware and innovative DeepInsight cell fingerprinting technology for the Biotech, Medical, and related microscopic imaging industries. Our solutions enable faster, more accurate results for researchers and clinicians.

TEK Optima Research combines cutting-edge hardware development with sophisticated data analytics and AI to deliver a complete imaging platform. We support a wide range of applications, from drug discovery to clinical diagnostics.

Founded in 2019, we’ve quickly established ourselves as a trusted partner for organizations seeking to push the boundaries of microscopic imaging. We currently employ a team of 5 dedicated professionals, operating from our R&D office and manufacturing facility in Dorset and a secondary R&D office in Durham, NC.

Genomics is a pioneering transatlantic TechBio company based in Oxford, UK, specializing in **genomic prevention** and transforming healthcare through the power of genomics.

We leverage large-scale genetic information to provide accurate, personalized risk estimates for common diseases and cancers, enabling early interventions and tailored screening. Our proprietary algorithms and databases link minute variations across the entire genome to biological measurements and disease outcomes, generating population-level insights for healthcare systems and individual-level risk assessments for clinicians.

Genomics partners with leading life sciences and biotech companies, including Novo Nordisk and Vertex, offering a unique approach to sustainable healthcare. Our team of over 150 experts – including world-leading genomic scientists, computational biologists, and data scientists – is dedicated to bringing subject-leading science to a global audience, ultimately transforming lives.

bio-bean is the world’s largest recycler of spent coffee grounds, recycling thousands of tonnes annually into sustainable bio-products. The UK drinks 98 million cups of coffee every day, creating a quarter of a million tonnes of spent coffee grounds every year. Typically, these grounds are sent to landfill where they emit greenhouse gases, including methane. Discarding in landfill is not only damaging to our environment, it is also a costly method of waste disposal for businesses due to the UK government’s landfill tax. Working within the existing logistics infrastructure to collect spent coffee grounds from businesses at every scale, we recycle these grounds into sustainable products for a variety of industries. At bio-bean we’re on a mission to reduce waste, reduce emissions and create a real difference for our world by sustainably innovating through coffee waste. As a B Corp™, sustainability is at the heart of everything we do. We’re in it for the long haul, creating impact built to last. Visit www.bio-bean.com to learn more.

AMPLY Discovery is a drug and nutraceutical discovery company based in Northern Ireland. A spin-out company from Queen's University Belfast, we use machine learning and AI to discover new therapeutic molecules for hard-to-treat diseases. This includes developing new drugs to replace conventional antibiotics and help tackle AMR. Our discovery platform is designed to mine vast biological datasets in silico and validate hundreds of hits in vitro.

We are the first in class pre-clinical translational biophysics company focusing on the discovery of novel therapeutics against intrinsically disordered targets.

Our mission at HexagonFab is to unlock the secrets of proteins and their interactions. We want to create the tools that enable anyone to understand how a protein behaves, what its properties are and how it interacts with other molecules, e.g. analysis of binding interactions for QC. Our tools help researchers to develop the medicine of the future, to find the best ways to produce novel biomolecules and to assure that medicine is always safe and efficacious. Our focus lies on convenient tools with high degree of automation and low hands-on time. We are a dynamic, interdisciplinary team working at the intersection of biology, nanotechnology and data science. We value a flat hierarchy, where everyone is encouraged to share their ideas and to follow their passion. We believe it is important to move fast, to make mistakes and then to try again.

I-Phyc is a natural solutions company, that harnesses the power of algae to remove phosphorus, ammonia and other contaminants from tertiary water while locking away carbon and creating sustainable products.

BDD Pharma combines drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and create new value-added products. Rapid parallel clinical testing with BDD SWIFT significantly reduces the time from product concept to clinical success. Recognizing that one size does not fit all we specialise in providing responsive, flexible and innovative solutions to our customers. Our patented delayed release technology OralogiK provides unrivalled control of drug release at the right place and time. Our clinical division provides a full clinical package, including protocol development, study documentation design and regulatory authority submission, through to close out and production of ICH GCP-compliant clinical study report. We specialise in gamma scintigraphy, a powerful and versatile technology used to investigate the in vivo behaviour of your formulation. Coupled with pharmacokinetic data, this technique can be used to provide information on time /site of disintegration, gastric emptying, GI transit and intra/ inter individual differences.

Dxcover is a clinical stage liquid biopsy company developing tests for the early detection of multiple cancers, when treatment has a better chance to impact outcomes. The company has pioneered the early detection and identification of cancer employing infrared spectroscopy of circulating pan-omic biomarkers. The company has generated compelling clinical data with high accuracy detection of Stage I and Stage II cancers. Dxcover is based in Scotland, United Kingdom and is establishing operations in the USA.

Eagle Genomics applies network science to biology. We are revealing the impact of the microbiome on humans, animals and the environment to secure a sustainable future for our food, water, soil and the health of our planet. Our mission is to deliver insight from the microbiome to profoundly change our understanding of wellness and even our fundamental assumptions about life on earth. Our platform transforms scientists’ journey to insights, unifying constellations of complex, multi-dimensional data (the data fabric) to explore and extract signals and networks of relationship, otherwise not detectable by humans alone. This is the frontier of science today and nowhere are the opportunities and challenges more significant than in the burgeoning field of the microbiome.

At abcam, we believe the scientific community goes further, faster when we go there together. And to keep on making ground-breaking discoveries, we need to work together in new ways. That’s why we’re constantly innovating to help scientists drive their research forward by providing products and solutions that play an essential role in fundamental research, drug discovery, diagnostic and therapeutic applications. We started with a simple mission: to provide the best biological reagents to life scientists worldwide. Today, we help 750,000 researchers in over 130 countries deliver faster breakthroughs in areas like cancer, neurological disorders, infectious diseases, and metabolic disorders.

Adapttech is a biomedical innovation company committed to bringing new smart technologies to the O&P market. We aim to empower clinicians with data-driven solutions and patient remote monitoring methods to improve the quality of life of lower-limb prosthetic users.

Automata was founded with a clear aim: to unlock human potential with automation. Through our collaboration with some of the world’s leading pathology labs, we’ve developed the most comprehensive lab automation platform on the market. By simplifying environments and empowering people, Automata enables labs to scale with precision and creates new opportunities for scientists to accelerate innovation.

We are Bicycle Therapeutics, a clinical-stage biopharmaceutical company. We didn’t wait for the next advance against cancer. We created it. Based on groundbreaking work conceived in the laboratory of Sir Greg Winter with the help of Professor Christian Heinis, we are pioneering the development of bicyclic peptides, or Bicycles® – a novel class of versatile, chemically synthesized medicines. Bicycles are fully synthetic short peptides constrained to form two loops which stabilize their structural geometry. This constraint is designed to confer high affinity and selectivity, and the relatively large surface area presented by the molecule allows targets to be drugged that have historically been intractable to non-biological approaches. Bicycles represent a unique therapeutic class, combining the pharmacological properties normally associated with a biologic with the manufacturing and pharmacokinetic advantages of a small molecule, yet with no signs of immunogenicity observed to date. Bicycles can be used as Bicycle conjugates to deliver toxin payloads and to precisely target local immune activation within tumors and as Bicycle T-cell modulators, which activate cytotoxic T-cells while circumventing the limitations of antibody and biologic therapies and better enabling combination therapy. Our lead product candidate, BT1718, is a Bicycle toxin conjugate currently being investigated in a Phase I/IIa open label dose escalation and expansion clinical trial sponsored by Cancer Research UK. BT1718 targets Membrane Type 1 Matrix Metalloproteinase (MT1-MMP), also known as MMP-14, which is highly expressed in many solid tumors. Our strategic collaborations are based on the ability of Bicycles to address a wide variety of targets. Through collaborations with AstraZeneca, Oxurion, Innovate UK and the Dementia Discovery Fund, we work with companies that have deep therapeutic expertise outside of oncology to enable us to more efficiently develop novel medicines for patients.

Biorelate helps scientists solving the most difficult biomedical challenges of today. We do this by curating truths from existing knowledge, enabling smarter and faster research & development.

bit.bio is an award-winning human synthetic biology enterprise. Our mission is coding cells for health. To do so, we apply the principles of computation to biology. Our current focus is to develop a scalable technology platform capable of producing consistent batches of every human cell. This has the potential to unlock a new generation of medicine: it will enable research and drug discovery to move on from inappropriate models and work with the cells that actually are affected by human disease. A scalable platform of consistent cells will also be the basis for a new generation of cell and tissue therapies. To achieve our goals, we have assembled a team of pioneers in stem cells, cellular reprogramming, mathematical modelling, and cell therapy. Collaboration is at the heart of bit.bio. We are empirical, highly ambitious and driven by a common purpose.

Zoono Animal Health UK is an accredited licensee for Zoono Animal Health antimicrobial products, bringing Zoono’s market-leading technology into the UK and European agricultural sector. Our vision is to provide the future of antimicrobial technology with animal health at the forefront. We strive to build productive relationships to make a positive impact on animal health. Our antimicrobial products are; - Proven to protect surfaces for up to 30 days from a single application - Water based, containing no harmful chemicals - Validated extensively by over 150 independent tests worldwide - Protects against 99.99% of known germs - Proven to generate significant Returns on Investment in the agricultural sector

Developing avant-garde computational pathology solutions to streamline pathologist workflows and help deliver personalised medicine.

BIOCAPTIVA is developing the BioCaptis, a revolutionary medical device which has the potential to transform liquid biopsy testing for cancer management, by improving early diagnosis and monitoring of disease and enhancing clinical trial data of cancer patients. The BioCaptis captures up to 100x more cell free DNA (cfDNA) than a venous blood draw, yielding cfDNA in high quality and quantity for testing, addressing the major challenge of liquid biopsy in cancer management. This will potentially allow the testing of a far greater number of cancer types and stages in a much wider range of patients. BIOCAPTIVA was founded in 2021 when it spun out from the University of Edinburgh. BIOCAPTIVA is based in Edinburgh and backed by Archangels Scottish Enterprise, Cancer Research Horizons, the new innovation engine of Cancer Research UK and Old College Capital, the University of Edinburgh’s in-house venture investment fund. For more information, please visit www.biocaptiva.com

We are interested in developing innovative hydrogels which will help shape the future of agriculture, environment and healthcare!

Relation is pioneering a “Lab-in-the-Loop” that can integrate active learning at every step of drug discovery, from predicting cell states to the validation of new targets. An important challenge for any therapeutics company using machine learning is “ground-truth data,” or information known to be true. Working from real cells provided by proprietary biobanks, Relation’s technology generates genomic data that provide direct insights into critical biological relationships that are fed directly into its ML systems. The platform then requests new experiments to improve its predictive ability, cutting through an otherwise intractable combinatorial space.

ENOUGHs purpose to ‘make protein sustainable’. Using fermentation to meet future food protein needs is widely recognised as the most effective solution to feed a growing planet. ENOUGH produces ABUNDA® mycoprotein, a complete food ingredient containing all essential amino acids as well as being high in dietary fibre. It is versatile and can be made into alternative/vegan meat, seafood and dairy products. The company will supply ABUNDA as a B2B (business to business) food ingredient to consumer brands and retailers, addressing the need for high scale supply of healthy and sustainable protein to address a rapidly growing market. The impact of introducing 1 million tonnes of ABUNDA mycoprotein by 2032 is equivalent to replacing 5 million cows, over a 1 billion chickens and reducing more than 5 million tonnes of CO2 emissions.

BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery and development company listed on the Euronext Amsterdam stock exchange. Through the combined capabilities of its AI platform, scientific expertise, and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform™ powers a growing in-house pipeline of 13 named drug programmes and over 10 exploratory programmes, and it maintains successful collaborations with AstraZeneca, as well as leading research and charitable institutions. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York. *Reach out to us* Email: hello@benevolent.ai Careers: Careers@benevolent.ai Twitter: @benevolent_ai Website: benevolent.com

Bionema is a leading biopesticide technology developer. We develop and provide chemical free, pest management solutions for the Horticulture, Turf & Amenity, Landscaping & Forestry, and Public Health sectors. With over 30 years' experience in research, development and commercialisation of biopesticides, we have a robust patent portfolio, and we have collected a library of more than a hundred commercially-viable microorganisms for pipeline candidates. Our formulation technologies can give biopesticides higher virulence, stability and spore yields, wider host ranges and higher kill rates. Our products include biopesticides, biostimulants, biofertilisers, efficacy boosters, biocides and pest monitoring traps. If you are interested in using these products, talk to one of our experts about the ones most suited to your needs, and how to use them most effectively. We work with exceptional researchers within universities and private companies around the world to develop natural products that use microorganisms and natural plant chemicals to manage insect pests, reducing the use of synthetic pesticides that can be harmful to people and the planet. If you are looking to collaborate to innovate, then look no further – Bionema can help! As well as developing novel products, Bionema supports researchers, developers and manufacturers of biopesticide products with: - Strain identification, selection and improvement - Production, formulation and application - Analytical and R&D solutions - Quality assessment of biological products - Supporting registration of biocontrol agents - Product efficacy testing - Knowledge transfer Bionema is based in Swansea University with a highly experienced team and access to well-equipped GEP accredited laboratories.

The World BioProtection Forum (WBF) is a non-profit organisation for encouraging collaboration between the biocontrol industry and academia in the AgriTech sector. Our goal is to ensure the successful development and commercialisation of biocontrol products, by helping our members to overcome challenges and leverage opportunities in a post-COVID, post-Brexit world. Our mission is to bridge the gap between academia and industry globally to ensure the successful development and commercialisation of biocontrol products. WBF connects innovators, entrepreneurs, researchers, manufacturers and distributors operating in the biocontrol sector.

We specialize in the creation of AI-powered imaging biomarkers to enable precision medicine for better treatment decisions. Since launching as a spin-out from the University of Oxford in 2010, we have developed award-winning, AI-powered imaging biomarkers and software solutions, assisting physicians across the world to make better life-saving decisions.

C4X Discovery aims to become the world's most productive drug discovery engine by exploiting cutting edge technologies to design and create best-in-class small-molecule candidates targeting a range of high value therapeutic areas. The company's goal is to drive returns through early-stage revenue-generating deals with the pharmaceutical industry. C4X Discovery has a state-of-the-art suite of proprietary technologies across the drug discovery process. The company's innovative DNA-based target identification platform (Taxonomy3(R)) utilises human genetic datasets to identify novel patient-specific targets leading to greater discovery productivity and increased probability of clinical success. This is complemented by C4XD's novel drug design platform which comprises two innovative chemistry technologies, Conformetrix and Molplex, that combine 4D molecular shape analyses (based on experimental data) with best-in-class computational chemistry. C4X Discovery is advancing its in-house pipeline that is primarily focused on the high value therapeutic areas of inflammation, neurodegeneration and cancer (including immuno-oncology) with a number of new drug candidates identified and further progress made towards the pre-clinical licensing discussions. In selecting new targets and executing new drug discovery programmes, C4X Discovery focuses on high-value disease areas that are the subject of significant licensing activity and will continue to also maximise value from opportunistic areas such as addiction and diabetes. The Company recently signed a licensing agreement with Indivior for a pre-clinical addiction programme worth up to $294m. The Company was founded as a spin-out from the University of Manchester. t has a highly experienced management team and Board who have delivered significant value creation within the healthcare sector historically and have enabled C4XD to reach multiple value inflexion points since IPO. Website: www.c4xdiscovery.com Twitter: @C4XDiscovery

Carocell Bio is revolutionising the treatment of skin-related inflammatory conditions with its peptide-based, next-generation approach to promoting healthier skin. Its pipeline of products, meant for topical application to the skin, is designed to interrupt the inflammatory cascade – potentially providing safer and novel therapeutic options to patients. This includes treating and preventing AD (eczema) and delaying skin ageing – a process strongly associated with inflammation. Carocell Bio’s therapeutic pipeline consists of a number of small proteins (called “peptides”) that target an enzyme known as mitogen-activated protein kinase (MAPK). MAPK plays a key role in inflammation. These peptides have been specially formulated for topical use. Its pipeline of products, meant for topical application to the skin, is designed to interrupt the inflammatory cascade – potentially providing safer and novel therapeutic options to patients. This includes treating and preventing AD (eczema) and delaying skin ageing – a process strongly associated with inflammation. Carocell Bio’s therapeutic pipeline consists of a number of small proteins (called “peptides”) that target an enzyme known as mitogen-activated protein kinase (MAPK). MAPK plays a key role in inflammation. These peptides have been specially formulated for topical use.

Cambridge Cancer Genomics (CCG.ai) are on a mission to ensure that each patient has the right drug, at the right time, to beat their cancer. We build the software to enable data-driven precision oncology and systematically develop data-driven biomarkers indicative of treatment response. We believe that increasing amounts of clinical and genomic data have the potential to transform cancer treatment, and enable oncologists to make smarter decisions about which drug to use in which circumstance.

CV6 Therapeutics is an early stage drug development company focused on the discovery, development and commercialization of novel combination therapies for the treatment of cancer. For further investment questions or opportunities please contact: information@cv6t.com

F-star, an invoX company, is a clinical-stage biopharmaceutical business pioneering bispecific antibodies in immunotherapy so more people with cancer can live longer and improved lives. F-star is committed to working towards a future free from cancer and other serious diseases through the use of tetravalent (2+2) bispecific antibodies to create a paradigm shift in treatments. F-star has four second-generation immunooncology therapeutics in the clinic, each directed against some of the most promising IO targets in drug development, including LAG-3 and CD137. F-star’s proprietary antibody discovery platform is protected by an extensive intellectual property estate, with over 500 granted patents and pending patent applications relating to its platform technology and product pipeline. The Company has attracted multiple partnerships with biopharma targeting significant unmet needs across several areas, including oncology, immunology, and CNS.

Fluidic Analytics designs, develops and manufactures tools that seek to revolutionise the way proteins are characterised, allowing our customers to understand the machinery of life. We envision a world where information about proteins and their behaviour transforms our understanding of how the biological world operates, and helps all of us make better decisions about how we diagnose diseases, develop treatments and maintain our personal well-being. By building the world’s best tools, software and services for protein characterisation and making them universally accessible in the lab, in the clinic or at home, we are making this vision a reality not just for a small group of expert users, but for everyone who can benefit. Twitter: @fluidicanalytic

IVF Bioscience aims to help develop the animal IVF market by improving yields through higher success rates. Using the IVF Bioscience media systems, laboratories benefit from our extensive portfolio of knowledge by achieving higher blastocyst rates, more robust blastocysts and thereby higher pregnancy rates.

Kynos Therapeutics is poised to bring a new generation of potent first-in-class KMO inhibitors to the market - ready to impact on unmet medical needs. Kynos Therapeutics Ltd. is a Private Limited Company Registered in England and Wales, Company number 12501037

LabGenius is the first biopharmaceutical company developing next generation protein therapeutics using a machine learning-driven evolution engine (EVA™). Our protein engineering platform integrates several bleeding edge technologies from the fields of machine learning, synthetic biology and robotics.

Gentronix is a specialist CRO focused on delivering predictive toxicology products & services to global chemical sectors. Working with companies from early screening through to regulatory safety assessment, we deliver innovative solutions for both genetic toxicology and skin sensitisation. For 20 years, Gentronix Ltd has provided predictive toxicology solutions to global chemical industries; enabling our clients to optimise their development programmes via early identification of genotoxic hazard and assessment of chemical safety. Gentronix offers a comprehensive portfolio of screening and regulatory genotoxicity products & services, along with assessment of skin sensitisation potential.

Imagen Therapeutics is a biotech company based in the UK, with an ongoing commitment to improving the outcomes of cancer patients by accelerating drug discovery and the development of new cancer therapies. Our main activities include offering personalised clinical diagnostic services to cancer patients, offering contract research services, and developing a world-leading well-characterised Biobank.

Metrion Biosciences is a UK-based Contract Research Organization specialising in high quality ion channel screening and drug development expertise. We aim to provide our customers with access to a range of in vitro screening services that includes cardiac safety (hERG, CiPA panel of human cardiac ion channels) and neurotoxicology testing and phenotypic assays on a fee-for-service or collaboration basis. We pride ourselves on being able to provide a flexible and cost effective service with an unparalleled level of expertise. Collectively, our management team have amassed over 80 years of experience in ion channel drug discovery and our clients can access this high level of expertise as part of our dedicated service.

Micrima was founded in 2006 to develop and commercialise microwave radar breast imaging technology initially pioneered at the University of Bristol in the UK. The company's MARIA system is currently in clinical trials to collect valuable data for our machine learning algorithm's. The latest step in the journey to Breast Screening will be launched in 2022. This new system will provide density information and improved ergonomics for patient and operator. Contact us to arrange to see this system or to find out more.

MicrobesNG is an innovative microbial genome sequencing service. We provide value driven whole genome and metagenome sequencing and bioinformatics analysis to our global customer base for microbial applications (including bacterial, fungal and viral samples.) Our journey so far has been amazing! Founded in 2014 within the University of Birmingham, with support of a BBSRC grant, we established our business and began to thrive. The next chapter in our evolution came in August 2019 when we “spun out” of the University after 5 years of successful operation. Since then it’s been onwards and upwards. We are on a mission to deliver high value, quality sequencing data within academia and the public and private sectors. We consistently strive to ensure that our service offerings and capabilities match those required by our customers. Providing a positive customer experience is at our core and we place our fantastic customers at the heart of everything we do. We enjoy a high percentage of repeat business demonstrating that we consistently deliver on our promises to our customers. Our highly qualified and experienced teams excel at delivering quality sequencing data for both “high volume” and “single sample” projects. Our service experience has made us specialists in coordinating projects involving multiple collaborators across different continents while incorporating the ability to deliver a personalised service. Our teams are always available to provide support and guidance for those customers that are new to microbial genome sequencing. MicrobesNG really is a sequencing service for all users!

Microbiotica identifies gut bacteria linked to phenotype with unprecedented precision in order to discover and develop live bacterial therapeutics and biomarkers from clinical datasets. Initially built out of 10 years investment in the Wellcome Sanger Institute, Microbiotica has unrivalled capabilities in microbiome analysis linked to patient phenotype. It is a global leader in gut bacterial culturing, and has a world leading microbiome Culture Collection, proprietary Reference Genome Database and advanced microbiome bioinformatics. The company also has advanced capabilities in microbiome/host biology and preclinical development of bacterial products. Microbiotica has a pipeline of highly differentiated clinically-derived products including Live Bacterial Therapeutics and Biomarkers in IBD, Immuno-oncology and Gut Epithelial Barrier Repair. It has collaborations with Cancer Research UK and Cambridge University Hospitals in Immuno-oncology, Genentech/Roche in IBD, and University of Adelaide in Ulcerative Colitis.

Mission Therapeutics is a private, drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat diseases of high unmet need. Mission has built a world-leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging, and hitherto intractable, drug class that is attracting significant commercial interest as the potential ‘Next Kinase Area’. Mission’s DUB platform is yielding a rich pipeline of novel therapeutics for the benefit of patients across therapeutic areas. Mission’s strategy is to create value by advancing its pipeline programmes through early clinical development, and preferentially with a patient selection strategy to enhance the probability of demonstrating early signs of efficacy. Mission’s leadership team has a wealth of international, commercial and scientific experience, and the company has strong links with key academic and research centers including Cancer Research UK Laboratories and the Jackson Laboratories at the Gurdon Institute, University of Cambridge. The Company has to date received £87 million in venture capital from a blue chip syndicate comprising institutional and corporate investors and was awarded a £1.9 million grant from Innovate UK in September 2015. In February 2016, the Company raised £60 million in a Series C financing led by Imperial Innovations and new investor Woodford Patient Capital Trust. It included follow-on investment from existing shareholders Sofinnova Partners, SR One, Roche Venture Fund and Pfizer Venture Investments. Mission is based at the Babraham Research Campus, south of Cambridge.

NeoPhore is creating novel small molecule immuno-oncology therapeutics. NeoPhore's drugs target genetic mechanisms that both clinical and lab validation studies suggest will promote neoantigen creation and diversity across numerous cancers. Alone or in combination with other cancer immunotherapies, drugs that spark cancer neoantigen creation are designed to stimulate the immune system and improve outcomes for patients who fail to benefit from the current generation of cancer immunity therapeutics.

We are a biotechnology-based company focused on the exploitation of marine biodiversity applied to human needs. The company was born with the objective of developing and bringing innovative solutions to the world for problems in different markets, using one of the richest and most diverse groups of organisms on the planet: microalgae. Research and development are the soul and engine of our company and therefore we constantly collaborate in research and development projects with the most recognized research centers and universities in the world. The founders of NEPTUNUS BIOTECH have more than 25 years of experience giving sustainable and innovative solutions to the agricultural industry. In addition to having a world-class and personal scientific council with more than 30 years working with microalgae, plants and other photosynthetic organisms. The technological platform of NEPTUNUS BIOTECH provides solutions to three different markets: agricultural, food and personal care.

Nuclera is making biology accessible by providing researchers a desktop bioprinter capable to produce genes and proteins in one day. Biological research and drug discovery projects begin with and rely on proteins. However, using traditional methods to obtain proteins of interest can take up to 6 months and often include many trials and failures. What if there was an easier way? At Nuclera, our mission is to better human health by making proteins accessible. We believe that providing rapid access to high-quality, soluble, active proteins at the benchtop will allow researchers to accelerate their protein projects. Fail fast, succeed faster. Our eProtein Discovery™ system automates construct screening for the best soluble expression and purification yields of different proteins in under 24 hours. From there, protein scale-up happens the next day (up to the mg scale) right on the benchtop - delivering reliable protein in-hand in less than 48 hours. Nuclera’s technology integrates cell-free protein synthesis and digital microfluidics on smart cartridges, allowing rapid progress on protein projects through a benchtop, automated, high-throughput protein access system. Founded in 2013 by PhD students at the University of Cambridge, the company now has a presence in Cambridge, UK and Boston, MA employing over 100 employees.

The North West Biotech Initiative (NWBI) provides a platform that encourages knowledge sharing and dialogue between young students, local and international businesses and industry experts. We promote the development of early stage researchers in the STEM fields by providing an inclusive space for fostering relationships between academia and the growing local biotech sector. This provides students the power of choice; to choose a career path based on interest and passion and not due to a lack of skills or opportunities. Thus, students will be prepared to apply in-demand professional skills in any arena and sector they choose to pursue in life beyond their academic institutions.

See protein, DNA and RNA molecules that make life work, in nanoparticles, viruses, bacteria, cells and tissue. We believe that understanding science at a molecular level will fundamentally allow you to unlock new discoveries, so we created our flagship product, The Nanoimager. We built the world's first desktop compatible compact super-resolution microscope, but we did it our way. Our teams have a restless enthusiasm to bring technologies like super-resolution to a new community of researchers and we continue working until barriers of accessibility and affordability are addressed. Our mission is to ensure research and collaboration tools are available to those willing to ask why or how things are the way they are and answer questions never asked before. We can’t wait to see and hear about what new questions you will ask!

With so much potential for biotech to make the world a better place to live, we knew we needed to make the lab a better place to work. We’re a team of scientists and designers who have meticulously studied the in-lab experience, getting a detailed understanding of workflows and identifying common pain points that routinely cost scientists time and money. Our BioHotel labs are designed with biotech startups in mind: - Short term, flexible leases - Central London locations in key life sciences clusters - BSL2 lab spaces that can be tailored to your workflow - Specialist services including cryogenic freezer storage, glassware washing and sterilisation and a lab coat laundry - Access to bookable specialist labs and equipment - All-inclusive clinical, chemical and general waste services - Discounts and free delivery from our store

Ori Biotech is a London- and New Jersey-based leader in CGT manufacturing technology that has developed a proprietary, bespoke and flexible manufacturing platform, which enables patient access to a new generation of personalised, lifesaving treatments. By fully automating and standardising CGT manufacturing in a closed platform, Ori offers therapeutics developers the opportunity to seamlessly scale from pre-clinical process development to commercial scale manufacturing. So complex manufacturing challenges can be put where they belong – in the past.